公开(公告)号：EP1711174A1

公开(公告)日：2006-10-18

申请号：EP05701990.3

申请日：2005-01-21

申请人： M N L Pharma Limited

发明人： NASH, Robert James ,  WATSON, Alison Ann ,  EVINSON, Emma Louisa

IPC分类号： A61K31/40 ,  A61P31/00 ,  A61P35/00 ,  C07D487/04 ,  C07D209/00 ,  C07H3/02

CPC分类号： A61K39/39 ,  A61K31/40 ,  A61K31/407 ,  A61K31/7028 ,  A61K38/208 ,  A61K45/06 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/57 ,  C07D487/04 ,  A61K2300/00

摘要： An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and/or MF59), a type 1 adjuvant and/or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s); polysaccharide(s) (e.g. carbohydrate(s)); fusion protein(s); lipid(s); glycolipid(s); peptide mimic(s) of polysaccharides carbohydrate(s) and a protein(s) in admixture; carbohydrate-protein conjugate(s); cells or extracts thereof; dead or attenuated cells or extracts thereof; tumour cells or extracts thereof; viral particles (e.g. attenuated viral particles or viral components); allergen(s) mixtures thereof.

公开(公告)号：EP1587480A2

公开(公告)日：2005-10-26

申请号：EP04703841.9

申请日：2004-01-21

申请人： M N L Pharma Limited

发明人： WATSON, Alison Ann ,  NASH, Robert James ,  EVINSON, Emma Louisa

IPC分类号： A61K6/00

CPC分类号： A61K47/26 ,  A61K31/407 ,  A61K31/7028 ,  A61K35/15 ,  A61K36/185 ,  A61K36/61 ,  A61K45/06 ,  C07D487/04 ,  C07H3/02 ,  Y02A50/409 ,  Y02A50/411 ,  A61K2300/00

摘要： Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula are disclosed. In these compounds R is selected from hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups. The compounds are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, hemorestoration, alleviation of immunosuppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells.

摘要翻译： 其中R选自氢，直链或支链，未取代或取代的，饱和或不饱和的酰基，烷基（例如环烷基），烯基，炔基和芳基的分离的免疫调节的（例如免疫刺激性）多羟基化吡咯烷啶化合物 基团或其药学上可接受的盐或衍生物可用于治疗和预防，包括增加Th1：Th2应答比率，愈合过程，减轻免疫抑制，细胞因子刺激，治疗增殖性病症（例如癌症），疫苗接种，刺激 先天性免疫应答和内源性NK细胞活性的增强。

公开(公告)号：EP1711176A1

公开(公告)日：2006-10-18

申请号：EP05701978.8

申请日：2005-01-21

申请人： M N L Pharma Limited

发明人： NASH, Robert James ,  WATSON, Alison Ann ,  EVINSON, Emma Louisa ,  PARRY, Hadyn St Pierre

IPC分类号： A61K31/407 ,  A61K31/7028 ,  A61K35/12 ,  A61P35/00

CPC分类号： A61K39/00 ,  A61K31/407 ,  A61K31/7028 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/55511 ,  Y02A50/41 ,  Y02A50/412

摘要： Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrrolin alkaloids; pyrrolidine alkaloids; pyrolizidine alkaloids: indolizidine alkaloids and nortropane alkaloids.